• linkedin
  • Increase Font
  • Sharebar

    A new castration-resistant prostate cancer entity?

    Brandon Manley, MDBrandon Manley, MD

    UT SUO 2015 Internship Member Profile


    Dr. Manley is a urologic oncology fellow at Memorial Sloan Kettering Cancer Center, New York. During the Society of Urologic Oncology 2015 winter meeting, he was one of several urologic oncology fellows to contribute articles to Urology Times through a collaborative “UT SUO Internship.” Urology Times extends its thanks to all of the fellows and the Society of Urologic Oncology for participating in this unique partnership. For other articles in this series, click here.

    Washington—A presentation at the 2015 Society of Urologic Oncology annual meeting in Washington highlighted several interesting findings about advanced prostate cancer with variant histology.    

    The presentation, titled “Intermediate Atypical Carcinoma: A New Castration Resistant Prostate Cancer (CRPC) Entity,” was presented by Eric Small, MD, of the University of California, San Francisco. Dr. Small leads a team of physicians and researchers called the “Dream Team” that is funded by the Prostate Cancer Foundation and Stand Up To Cancer. One of the team’s goals is to find new ways to improve the management of patients with metastatic and treatment-resistant prostate cancer.

    Dr. Small described an emerging pathologic finding in many of the patients that he and his team study. About one-third of patients with CRPC in their study who have biopsies of metastatic lesions, have pathology that is different than typical adenocarcinoma, he reported. This entity has pathologic and genetic characteristics different than small cell or neuroendocrine carcinoma, which is one of the more common prostate cancer variants. They have given this pathology the name Intermediate Atypical Carcinoma (IAC).

    Next: A “clinically very important subtype”


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available